Reactivation of latent tuberculosis infection following initiation of tofacitinib therapy for rheumatoid arthritis: A case report
Background: Latent tuberculosis infection (LTBI) reactivation is a well-known risk associated with immunosuppressive therapies employed in the treatment of rheumatoid arthritis (RA). Tofacitinib, an approved medication for RA that inhibits Janus kinases, has been associated with an elevated risk of...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Journal of Orthopaedic Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2773157X23000681 |